Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a report issued on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and set a $5.00 price target on shares of Trevena in a research report on Thursday, November 14th.

Trevena Trading Up 1.6 %

Shares of TRVN opened at $1.86 on Wednesday. The company’s 50-day moving average price is $1.70 and its 200 day moving average price is $3.17. Trevena has a 12-month low of $1.13 and a 12-month high of $17.51. The firm has a market cap of $1.60 million, a P/E ratio of -0.04 and a beta of 1.05.

Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share (EPS) for the quarter. The firm had revenue of $0.28 million for the quarter. Equities research analysts forecast that Trevena will post -23.04 earnings per share for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.